Psychobehavioural and cognitive adverse events of anti-seizure medications for the treatment of developmental and epileptic encephalopathies

A Strzelczyk, S Schubert-Bast - CNS drugs, 2022 - Springer
The developmental and epileptic encephalopathies encompass a group of rare syndromes
characterised by severe drug-resistant epilepsy with onset in childhood and significant …

Developmental and epileptic encephalopathies: what we do and do not know

N Specchio, P Curatolo - Brain, 2021 - academic.oup.com
Developmental encephalopathies, including intellectual disability and autistic spectrum
disorder, are frequently associated with infant epilepsy. Epileptic encephalopathy is used to …

Efficacy and safety of fenfluramine for the treatment of seizures associated with Lennox-Gastaut syndrome: a randomized clinical trial

KG Knupp, IE Scheffer, B Ceulemans… - JAMA …, 2022 - jamanetwork.com
Importance New treatment options are needed for patients with Lennox-Gastaut syndrome
(LGS), a profoundly impairing, treatment-resistant, developmental and epileptic …

DBS of thalamic centromedian nucleus for Lennox–Gastaut syndrome (ESTEL trial)

LJ Dalic, AEL Warren, KJ Bulluss… - Annals of …, 2022 - Wiley Online Library
Objective Prior uncontrolled studies have reported seizure reductions following deep brain
stimulation (DBS) in patients with Lennox–Gastaut syndrome (LGS), but evidence from …

Emerging use of epidiolex (cannabidiol) in epilepsy

R Abu-Sawwa, B Scutt, Y Park - The Journal of Pediatric …, 2020 - meridian.allenpress.com
The first plant-derived, purified pharmaceutical-grade cannabidiol (CBD) medication,
Epidiolex, was approved in the United States by the FDA on June 25, 2018. Its approval for …

Long‐term safety and efficacy of add‐on cannabidiol in patients with Lennox–Gastaut syndrome: Results of a long‐term open‐label extension trial

AD Patel, M Mazurkiewicz‐Bełdzińska, RF Chin… - …, 2021 - Wiley Online Library
Summary Objective Lennox–Gastaut syndrome (LGS) is an epileptic encephalopathy that is
often treatment resistant. Efficacy and safety of add‐on cannabidiol (CBD) to treat seizures …

A phase 2, randomized, double‐blind, placebo‐controlled study to evaluate the efficacy and safety of soticlestat as adjunctive therapy in pediatric patients with Dravet …

CD Hahn, Y Jiang, V Villanueva, M Zolnowska… - …, 2022 - Wiley Online Library
Objective Dravet syndrome (DS) and Lennox–Gastaut syndrome (LGS) are rare treatment‐
resistant childhood epilepsies classed as developmental and epileptic encephalopathies …

Cannabidiol in patients with Lennox‐Gastaut syndrome: Interim analysis of an open‐label extension study

E Thiele, E Marsh, M Mazurkiewicz‐Beldzinska… - …, 2019 - Wiley Online Library
Summary Objective Patients with Lennox‐Gastaut syndrome (LGS) who completed 1 of 2
randomized, double‐blind, placebo‐controlled trials of add‐on cannabidiol …

A comprehensive review of emerging trends and innovative therapies in epilepsy management

S Ghosh, JK Sinha, S Ghosh, H Sharma, R Bhaskar… - Brain Sciences, 2023 - mdpi.com
Epilepsy is a complex neurological disorder affecting millions worldwide, with a substantial
number of patients facing drug-resistant epilepsy. This comprehensive review explores …

An emerging role for sigma-1 receptors in the treatment of developmental and epileptic encephalopathies

P Martin, T Reeder, J Sourbron, PAM de Witte… - International journal of …, 2021 - mdpi.com
Developmental and epileptic encephalopathies (DEEs) are complex conditions
characterized primarily by seizures associated with neurodevelopmental and motor deficits …